Amgen Inc. (AMGN) stock is experiencing downward pressure following mixed clinical trial results for its obesity drug pipeline. This setback, combined with broader market rotation within the biotech sector, is impacting investor sentiment.
Amgen Shares Under Pressure Amid Pipeline Setbacks, Sector Rotation
Amgenbiotechclinical trialsobesity drugstock pressuresector rotation
